Therma Bright Inc.

Therma Bright is a progressive medical device technology company focused on providing consumers and medical professionals with quality medical devices that address their medical and healthcare needs. Therma Bright received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation of a variety of insect bites or stings. The Company received clearance for the above claims from the US FDA in 1997.

Recent News

  • Therma Bright Provides Update on Brazilian Performance Study of its AcuVid(TM) COVID-19 Rapid Saliva-Based Antigen Test

    Toronto, Ontario--(Newsfile Corp. - April 13, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of the AcuVid™ Covid-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that an initial phase of the Brazilian study of the AcuVid™ saliva-based rapid antigen test has been completed. Dr. Ricardo Fujiwara, from the Federal University of Minas Gerais, stated that, "The AcuVid™ initial results confirm the sensitivity and specificity results achieved in...

    2021-04-13 8:00 AM ET
  • Therma Bright Receives IRB Approval and Submits Application to Health Canada to Begin Clinical Study for its AcuVid(TM) COVID-19 Rapid Saliva-Based Antigen Test

    Toronto, Ontario--(Newsfile Corp. - March 25, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of the AcuVid™ Covid-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that it has received IRB approval and subsequently submitted to Health Canada seeking approval to conduct a clinical performance study of its AcuVidTM Covid-19 Rapid Saliva-based Antigen Test.Therma's clinical research organization prepared and filed the necessary documentation for the IRB and Health...

    2021-03-25 8:00 AM ET
  • Therma Bright Partners with Ridge Global to Expand Its United States and Global Reach

    Toronto, Ontario--(Newsfile Corp. - March 24, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of the AcuVidTM COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, announces that it has entered into business agreement with Ridge Global, the consultancy founded by Governor Tom Ridge, the first U.S. Secretary of Homeland Security. The agreement focuses on supporting the Company's reach across the United States and Global marketplace business community along with extending policy...

    2021-03-24 7:00 AM ET
  • Therma Bright Initiates Clinical Performance Study in Brazil for its AcuVid(TM) COVID-19 Rapid Saliva-Based Antigen Test

    Toronto, Ontario--(Newsfile Corp. - March 18, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that it has entered into an agreement with Safetest Diagnósticos("Safetest") of Brazil in partnership with the Federal University of Minas Gerais to conduct a clinical performance study of its AcuVidTM COVID-19 Rapid Saliva-based Antigen Test.Brazil's increase in its COVID-19 infection rate in the past week set another record in terms of new cases...

    2021-03-18 8:15 AM ET
  • Therma Bright Submits Application to Research Ethics Board for Approval of Clinical Trials for AcuVid(TM) COVID-19 Rapid Saliva-Based Antigen Test

    Toronto, Ontario--(Newsfile Corp. - March 11, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that it has submitted an application to an independent Research Ethics Board ("REB") for approval to conduct a clinical study with the Company's AcuVid TM rapid antigen test for detecting SARS CoV-2 virus in saliva. Approval is expected within a week, at which point Therma will submit a complete package, including the...

    2021-03-11 8:00 AM ET
  • Therma Bright Enters into Clinical Trial Agreement for its AcuVid(TM) COVID-19 Rapid Saliva-Based Antigen Test

    Toronto, Ontario--(Newsfile Corp. - February 26, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that it has entered into an agreement with a COVID-19 testing site located in the Greater Toronto Area to conduct a clinical study with the Company's AcuVid TM rapid antigen test for detecting SARS-CoV-2 virus in saliva. The testing site is located within the Greater Toronto Area that has one of the highest...

    2021-02-26 10:13 AM ET
  • Therma Bright Adds $1,171,875 to Treasury Through Exercise of Warrants and Options

    Toronto, Ontario--(Newsfile Corp. - January 29, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that in the past month, investors have exercised a total of 7,582,500 warrants and options to add $1,171,875 to the Company's treasury. With the addition of the $300,000, as previously reported in the press release on December 24th, 2020, the Company has added a total of $1,471,875 to the Company's treasury...

    2021-01-29 9:42 AM ET
  • Therma Bright Acquires 100% Control of its COVID-19 Rapid Saliva Antigen Test and Announces Proposed Name Change for the Test

    Toronto, Ontario--(Newsfile Corp. - January 25, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma Bright" or the "Company"), a progressive medical device technology company announces that it has taken 100% control of the research and development, regulatory, manufacturing and commercialization of its saliva-based rapid antigen test. As a result, Therma Bright will retain 100% of all future revenue and profits from the sale of the saliva-based rapid antigen test. Therma Bright previously announced on November 4, 2020, that...

    2021-01-25 7:30 AM ET